
Proposed shareholder suit alleges GeneDx misled investors about the Fabric acquisition’s expected benefits and the impact of problems with Fabric on GeneDx’s business.
Investors who bought GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 have until Aug. 3, 2026 to seek appointment as lead plaintiff in a pending securities class action. The lawsuit alleges GeneDx made misleading statements during that period about the impact of the Fabric acquisition, including claims that combining capabilities and algorithms between GeneDx and Fabric would reduce costs and improve efficiency. According to the complaint, those statements were false because defendants knew of, or recklessly disregarded, significant problems affecting Fabric’s viability that would negatively affect GeneDx’s business and operations. Rosen Law Firm said the case has already been filed and that investors may be able to pursue compensation without upfront out-of-pocket costs through a contingency fee arrangement.